Logo
Login
$BOLT
$6.37 -$0.22 (3.34%) Close

Company Executives

$BOLT Management Team

Mr. William Quinn

President

Chief Executive Officer

Chief Financial Officer

Director

Age 54
Compensation $1.203M USD
Sex Male

Mr. Grant Yonehiro

Chief Operating Officer

Age 61
Compensation $948.4K USD
Sex Male

Board of Directors

From the proxy statement filed Apr 28, 2026
Directors
6
serving now
Independent
4 of 6
stated in the proxy
Average tenure
4.0 years
from year joined
CEO also chairs the board
No
Brian O’Callaghan
Director Age On board Independent Committees Other public boards 2025 pay Source
William P. Quinn
CEO, Executive officer
 55 2024
2 years
 Not independent None stated None stated Paid as CEO
Jakob Dupont, M.D.
61 2024
2 years
 Not independent None stated Pyxis Oncology, Inc., Imugene Limited $191,841
Kathleen LaPorte
64 2020
6 years
 Independent
Audit Committee · Chair
89bio, CERo Therapeutics Holdings, Inc., Q32 Bio, Precipio Diagnostics $600,249
Nicole Onetto, M.D.
73 2021
5 years
 Independent
Nominating and Corporate Governance Committee
Basilea Pharmaceutica AG $310,700
Laura Berner
51 2022
4 years
 Independent
Nominating and Corporate Governance Committee · Chair
None stated $173,672
Brian O’Callaghan
Board chair
 56 2021
5 years
 Independent
Compensation Committee · Chair
Indaptus Therapeutics, Inc. $448,937

Each director opens the passage of the proxy that names them. "Not stated" means the proxy does not say; it never means "no". Pay is the proxy's Director Compensation table; the CEO is paid as an executive.

Related-party transactions

4 disclosed in the proxy filed Apr 28, 2026
Dr. Engleman
member of our Board until May 2024; professor at Stanford; co-inventor of patents licensed from Stanford
$91,800
2024

Payments to Stanford under license agreement for annual license fees and patent expense reimbursement

With Stanford University Open in proxy
Dr. Engleman
member of our Board until May 2024; professor at Stanford; co-inventor of patents licensed from Stanford
$62,200
2025

Payments to Stanford under license agreement for annual license fees and patent expense reimbursement

With Stanford University Open in proxy
Dr. Engleman
member of our Board until May 2024; professor at Stanford; co-inventor of patents licensed from Stanford
Amount not stated

As co-inventor, Dr. Engleman is entitled to a share of royalties paid to Stanford under the license agreements; no royalty payments have been made to date

With Stanford University Open in proxy
Dr. Jakob Dupont
Not stated in this section
Amount not stated
2025

Consulting agreement to provide services as a Senior Clinical Advisor; terminated February 2026

Open in proxy

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Premium Feature

This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.

Premium includes:

  • Unlimited historical financial data
  • Advanced analytics and insights
  • Priority support
View Pricing Plans